Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,404
Out of 4,755 analysts
11
Total ratings
9.09%
Success rate
-43.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $3.49 | +616.33% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.01 | +397.51% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $1.58 | +406.33% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $0.46 | +2,090.58% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $28.21 | +197.82% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $11.92 | +235.57% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $6.50 | +69.23% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $4.36 | +60.55% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $3.83 | +448.30% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $180 | $1.01 | +17,721.78% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $3.49
Upside: +616.33%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.01
Upside: +397.51%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $1.58
Upside: +406.33%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $0.46
Upside: +2,090.58%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $28.21
Upside: +197.82%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $11.92
Upside: +235.57%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $6.50
Upside: +69.23%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $4.36
Upside: +60.55%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $3.83
Upside: +448.30%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $180
Current: $1.01
Upside: +17,721.78%